Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel plus Cisplatin in advanced biliary tract cancer
NCT04692051Phase 2Unknown
- Sponsor
- Huazhong University of Science and Technology
- Start
- Sep 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paclitaxel in biliary tract cancer (BTC), sponsored by Huazhong University of Science and Technology. Primary endpoint: Progression-Free Survival at 3 years. Status: unknown.
02
Drugs
paclitaxel
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04692051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04692051.